Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents

References

• Opferman JT, Korsmeyer SJ. Apoptosis in the development and maintenance of the immune system. Nat Immunol. 2003;4(5):410–415. [Epub 2003 Apr 30].
   PubMed Web of Science ®Google Scholar
• Degterev A, Yuan J. Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol. 2008;9(5):378–390. [Epub 2008 Apr 17].
   PubMed Web of Science ®Google Scholar
• Lockshin RA. Programmed cell death 50 (and beyond). Cell Death Differ. 2016;23:10–17.
   PubMed Web of Science ®Google Scholar
• Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol. 1995;146(1):3–15.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Vandenabeele P, et al. Classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ. 2009;16(1):3–11. [Epub 2008 Oct 11].
   PubMed Web of Science ®Google Scholar
• Linkermann A, Green DR. Necroptosis. N Engl J Med. 2014;370(5):455–465. [Epub 2014 Jan 31]
   PubMed Web of Science ®Google Scholar
• Chan FK, Luz NF, Moriwaki K. Programmed necrosis in the cross talk of cell death and inflammation. Annu Rev Immunol. 2015;33:79–106. [Epub 2014 Dec 11].
   PubMed Web of Science ®Google Scholar
• Christofferson DE, Li Y, Yuan J. Control of life-or-death decisions by RIP1 kinase. Annu Rev Physiol. 2014;76:129–150. [Epub 2013 Oct 2].
   PubMed Web of Science ®Google Scholar
• Nikoletopoulou V, Markaki M, Palikaras K, et al. Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta. 2013;1833(12):3448–3459. [Epub 2013 Jun 19].
   PubMed Web of Science ®Google Scholar
• Wu W, Liu P, Li J. Necroptosis: an emerging form of programmed cell death. Crit Rev Oncol Hematol. 2012;82(3):249–258. [Epub 2011 Oct 4].
   PubMed Web of Science ®Google Scholar
• Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J Immunol. 1988;141(8):2629–2634. [Epub 1988 Oct 15].
   PubMed Web of Science ®Google Scholar
• Vercammen D, Beyaert R, Denecker G, et al. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med. 1998;187(9):1477–1485. [Epub 1998 June 6].
   PubMed Web of Science ®Google Scholar
• Holler N, Zaru R, Micheau O, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol. 2000;1(6):489–495. [Epub 2001 Mar 23].
   PubMed Web of Science ®Google Scholar
• Lin Y, Choksi S, Shen HM, et al. Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation. J Biol Chem. 2004;279(11):10822–10828. [Epub 2004 Jan 1].
   PubMed Web of Science ®Google Scholar
• Cho YS, Challa S, Moquin D, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell. 2009;137(6):1112–1123. [Epub 2009 Jun 16].
   PubMed Web of Science ®Google Scholar
• He S, Wang L, Miao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-α. Cell. 2009;137(6):1100–1111. [Epub 2009 Jun 16].
   PubMed Web of Science ®Google Scholar
• Zhang DW, Shao J, Lin J, et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science. 2009;325(5938):332–336. [Epub 2009 Jun 06].
   PubMed Web of Science ®Google Scholar
• Wallach D. Cell death induction by TNF: a matter of self control. Trends Biochem Sci. 1997;22(4):107–109. [Epub 1997 Apr 1].
   PubMed Web of Science ®Google Scholar
• Pennarun B, Meijer A, de Vries EG, et al. Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta. 2010;1805(2):123–140. [Epub 2009 Dec 8].
   PubMed Web of Science ®Google Scholar
• Fiers W, Beyaert R, Declercq W, et al. More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene. 1999;18(54):7719–7730. [Epub 2000 Jan 5].
   PubMed Web of Science ®Google Scholar
• Chan FK, Shisler J, Bixby JG, et al. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. J Biol Chem. 2003;278(51):51613–51621. [Epub 2003 Oct 9].
   PubMed Web of Science ®Google Scholar
• Jouan-Lanhouet S, Arshad MI, Piquet-Pellorce C, et al. TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation. Cell Death Differ. 2012;19(12):2003–2014. [Epub 2012 July 21].
   PubMed Web of Science ®Google Scholar
• Duprez L, Takahashi N, Van Hauwermeiren F, et al. RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity. 2011;35(6):908–918. [Epub 2011 Dec 27].
   PubMed Web of Science ®Google Scholar
• Linkermann A, Brasen JH, Darding M, et al. Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2013;110(29):12024–12029. [Epub 2013 Jul 3].
   PubMed Web of Science ®Google Scholar
• Feoktistova M, Geserick P, Kellert B, et al. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell. 2011;43(3):449–463. [Epub 2011 Jul 9].
   PubMed Web of Science ®Google Scholar
• Upton JW, Kaiser WJ, Mocarski ES. Virus inhibition of RIP3-dependent necrosis. Cell Host Microbe. 2010;7(4):302–313. [Epub 2010 Apr 24].
   PubMed Web of Science ®Google Scholar
• Martinon F, Gaide O, Petrilli V, et al. NALP inflammasomes: a central role in innate immunity. Semin Immunopathol. 2007;29(3):213–229. [Epub 2007 Aug 19].
   PubMed Web of Science ®Google Scholar
• Kalai M, Van Loo G, Vanden Berghe T, et al. Tipping the balance between necrosis and apoptosis in human and murine cells treated with interferon and dsRNA. Cell Death Differ. 2002;9(9):981–994. [Epub 2002 Aug 16].
   PubMed Web of Science ®Google Scholar
• Matsumura H, Shimizu Y, Ohsawa Y, et al. Necrotic death pathway in Fas receptor signaling. J Cell Biol. 2000;151(6):1247–1256. [Epub 2000 Dec 21].
   PubMed Web of Science ®Google Scholar
• Vercammen D, Brouckaert G, Denecker G, et al. Dual signaling of the Fas receptor: initiation of both apoptotic and necrotic cell death pathways. J Exp Med. 1998;188(5):919–930. [Epub 1998 Sept 9].
   PubMed Web of Science ®Google Scholar
• Fulda S. The mechanism of necroptosis in normal and cancer cells. Cancer Biol Ther. 2013;14(11):999–1004. [Epub 2013 Sept 13].
   PubMed Web of Science ®Google Scholar
• Christofferson DE, Yuan J. Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol. 2010;22(2):263–268. [Epub 2010 Jan 5].
   PubMed Web of Science ®Google Scholar
• Cho Y, McQuade T, Zhang H, et al. RIP1-dependent and independent effects of necrostatin-1 in necrosis and T cell activation. PLoS One. 2011;6(8):e23209. [Epub 2011 Aug 20].
   Google Scholar
• Kaiser WJ, Upton JW, Mocarski ES. Viral modulation of programmed necrosis. Curr Opin Virol. 2013;3(3):296–306. [Epub 2013 Jun 19].
   PubMed Web of Science ®Google Scholar
• Degterev A, Hitomi J, Germscheid M, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008;4(5):313–321. [Epub 2008 Apr 15].
   PubMed Web of Science ®Google Scholar
• Smith CC, Davidson SM, Lim SY, et al. Necrostatin: a potentially novel cardioprotective agent? Cardiovasc Drugs Ther. 2007;21(4):227–233. [Epub 2007 Aug 1].
   PubMed Web of Science ®Google Scholar
• Lin J, Li H, Yang M, et al. A role of RIP3-mediated macrophage necrosis in atherosclerosis development. Cell Rep. 2013;3(1):200–210. [Epub 2013 Jan 22].
   PubMed Web of Science ®Google Scholar
• Linkermann A, Brasen JH, Himmerkus N, et al. Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury. Kidney Int. 2012;81(8):751–761. [Epub 2012 Jan 13].
   PubMed Web of Science ®Google Scholar
• Oerlemans MI, Liu J, Arslan F, et al. Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo. Basic Res Cardiol. 2012;107(4):270. [Epub 2012 May 4].
   PubMed Web of Science ®Google Scholar
• Wu J, Huang Z, Ren J, et al. Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis. Cell Res. 2013;23(8):994–1006. [Epub 2013 Jul 10].
   PubMed Web of Science ®Google Scholar
• Gunther C, Martini E, Wittkopf N, et al. Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis. Nature. 2011;477(7364):335–339. [Epub 2011 Sep 17].
   PubMed Web of Science ®Google Scholar
• Welz PS, Wullaert A, Vlantis K, et al. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature. 2011;477(7364):330–334. [Epub 2011 Aug 2].
   PubMed Web of Science ®Google Scholar
• Re DB, Le Verche V, Yu C, et al. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron. 2014;81(5):1001–1008. [Epub 2014 Feb 11].
   PubMed Web of Science ®Google Scholar
• Zhu S, Zhang Y, Bai G, et al. Necrostatin-1 ameliorates symptoms in R6/2 transgenic mouse model of Huntington’s disease. Cell Death Dis. 2011;2:e115. [Epub 2011 Mar 2].
   PubMed Web of Science ®Google Scholar
• Xu X, Chua CC, Kong J, et al. Necrostatin-1 protects against glutamate-induced glutathione depletion and caspase-independent cell death in HT-22 cells. J Neurochem. 2007;103(5):2004–2014. [Epub 2007 Sep 1].
   PubMed Web of Science ®Google Scholar
• Li Y, Yang X, Ma C, et al. Necroptosis contributes to the NMDA-induced excitotoxicity in rat’s cultured cortical neurons. Neurosci Lett. 2008;447(2–3):120–123. [Epub 2008 Aug 30].
   PubMed Web of Science ®Google Scholar
• Yamanaka K, Saito Y, Yamamori T, et al. 24(S)-hydroxycholesterol induces neuronal cell death through necroptosis, a form of programmed necrosis. J Biol Chem. 2011;286(28):24666–24673. [Epub 2011 May 27].
   PubMed Web of Science ®Google Scholar
• Rock KL, Latz E, Ontiveros F, et al. The sterile inflammatory response. Annu Rev Immunol. 2010;28:321–342.
   PubMed Web of Science ®Google Scholar
• Linkermann A, Stockwell BR, Krautwald S, et al. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat Rev Immunol. 2014;14(11):759–767.
   PubMed Web of Science ®Google Scholar
• Wallach D, Kang TB, Kovalenko A. Concepts of tissue injury and cell death in inflammation: a historical perspective. Nat Rev Immunol. 2014;14(1):51–59. [Epub 2013 Dec 18].
   PubMed Web of Science ®Google Scholar
• Kim SK, Kim WJ, Yoon JH, et al. Upregulated RIP3 expression potentiates MLKL phosphorylation-mediated programmed necrosis in toxic epidermal necrolysis. J Invest Dermatol. 2015;135(8):2021–2030. [Epub 2015 Mar 10].
   PubMed Web of Science ®Google Scholar
• Ofengeim D, Ito Y, Najafov A, et al. Activation of necroptosis in multiple sclerosis. Cell Rep. 2015;10(11):1836–1849. [Epub 2015 Mar 25].
   PubMed Web of Science ®Google Scholar
• Christofferson DE, Li Y, Hitomi J, et al. A novel role for RIP1 kinase in mediating TNFα production. Cell Death Dis. 2012;3:e320. [Epub 2012 Jun 15].
   PubMed Web of Science ®Google Scholar
• Wang H, Sun L, Su L, et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell. 2014;54(1):133–146. [Epub 2014 Apr 8].
   PubMed Web of Science ®Google Scholar
• Murakami Y, Matsumoto H, Roh M, et al. Programmed necrosis, not apoptosis, is a key mediator of cell loss and DAMP-mediated inflammation in dsRNA-induced retinal degeneration. Cell Death Differ. 2014;21(2):270–277. [Epub 2013 Aug 21].
   PubMed Web of Science ®Google Scholar
• Sharma A, Matsuo S, Yang WL, et al. Receptor-interacting protein kinase 3 deficiency inhibits immune cell infiltration and attenuates organ injury in sepsis. Crit Care. 2014;18(4):R142. [Epub 2014 Jul 6].
   PubMed Web of Science ®Google Scholar
• Vitner EB, Salomon R, Farfel-Becker T, et al. RIPK3 as a potential therapeutic target for Gaucher’s disease. Nat Med. 2014;20(2):204–208. [Epub 2014 Jan 21].
   PubMed Web of Science ®Google Scholar
• Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1(2):112–119. [Epub 2006 Jan 13].
   PubMed Web of Science ®Google Scholar
• Artal-Sanz M, Tavernarakis N. Proteolytic mechanisms in necrotic cell death and neurodegeneration. FEBS Lett. 2005;579(15):3287–3296. [Epub 2005 Jun 10].
   PubMed Web of Science ®Google Scholar
• Brouckaert G, Kalai M, Krysko DV, et al. Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production. Mol Biol Cell. 2004;15(3):1089–1100. [Epub 2003 Dec 12].
   PubMed Web of Science ®Google Scholar
• Vandenabeele P, Galluzzi L, Vanden Berghe T, et al. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol. 2010;11(10):700–714. [Epub 2010 Sep 9].
   PubMed Web of Science ®Google Scholar
• Wang K, Li J, Degterev A, et al. Structure-activity relationship analysis of a novel necroptosis inhibitor, Necrostatin-5. Bioorg Med Chem Lett. 2007;17(5):1455–1465. [Epub 2007 Feb 3].
   PubMed Web of Science ®Google Scholar
• Teng X, Degterev A, Jagtap P, et al. Structure-activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett. 2005;15(22):5039–5044. [Epub 2005 Sep 13].
   PubMed Web of Science ®Google Scholar
• Teng X, Keys H, Jeevanandam A, et al. Structure-activity relationship study of [1,2,3]thiadiazole necroptosis inhibitors. Bioorg Med Chem Lett. 2007;17(24):6836–6840. [Epub 2007 Oct 30].
   PubMed Web of Science ®Google Scholar
• Jagtap PG, Degterev A, Choi S, et al. Structure-activity relationship study of tricyclic necroptosis inhibitors. J Med Chem. 2007;50(8):1886–1895. [Epub 2007 Mar 17].
   PubMed Web of Science ®Google Scholar
• Xie T, Peng W, Liu Y, et al. Structural basis of RIP1 inhibition by necrostatins. Structure. 2013;21(3):493–499.
   PubMed Web of Science ®Google Scholar
• Rosenbaum DM, Degterev A, David J, et al. Necroptosis, a novel form of caspase-independent cell death, contributes to neuronal damage in a retinal ischemia-reperfusion injury model. J Neurosci Res. 2010;88(7):1569–1576. [Epub 2009 Dec 22].
   PubMed Web of Science ®Google Scholar
• Lim SY, Davidson SM, Mocanu MM, et al. The cardioprotective effect of necrostatin requires the cyclophilin-D component of the mitochondrial permeability transition pore. Cardiovasc Drugs Ther. 2007;21(6):467–469. [Epub 2007 Oct 30].
   PubMed Web of Science ®Google Scholar
• Zhang A, Mao X, Li L, et al. Necrostatin-1 inhibits Hmgb1-IL-23/IL-17 pathway and attenuates cardiac ischemia reperfusion injury. Transpl Int. 2014;27(10):1077–1085. [Epub 2014 May 9].
   PubMed Web of Science ®Google Scholar
• You Z, Savitz SI, Yang J, et al. Necrostatin-1 reduces histopathology and improves functional outcome after controlled cortical impact in mice. J Cereb Blood Flow Metab. 2008;28(9):1564–1573. [Epub 2008 May 22].
   PubMed Web of Science ®Google Scholar
• Northington FJ, Chavez-Valdez R, Graham EM, et al. Necrostatin decreases oxidative damage, inflammation, and injury after neonatal HI. J Cereb Blood Flow Metab. 2011;31(1):178–189. [Epub 2010 Jun 24].
   PubMed Web of Science ®Google Scholar
• Dong K, Zhu H, Song Z, et al. Necrostatin-1 protects photoreceptors from cell death and improves functional outcome after experimental retinal detachment. Am J Pathol. 2012;181(5):1634–1641. [Epub 2012 Sep 4].
   PubMed Web of Science ®Google Scholar
• Takemoto K, Hatano E, Iwaisako K, et al. Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminophen-induced acute liver failure. FEBS Open Bio. 2014;4:777–787. [Epub 2014 Oct 29].
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang H, Tao Y, et al. Necroptosis inhibitor necrostatin-1 promotes cell protection and physiological function in traumatic spinal cord injury. Neuroscience. 2014;266:91–101. [Epub 2014 Feb 25].
   PubMed Web of Science ®Google Scholar
• Liu ZY, Wu B, Guo YS, et al. Necrostatin-1 reduces intestinal inflammation and colitis-associated tumorigenesis in mice. Am J Cancer Res. 2015;5(10):3174–3185. [Epub 2015 Dec 23].
   PubMed Web of Science ®Google Scholar
• Dmitriev YV, Minasian SM, Demchenko EA, et al. Study of cardioprotective effects of necroptosis inhibitors on isolated rat heart subjected to global ischemia-reperfusion. Bull Exp Biol Med. 2013;155(2):245–248. [Epub 2013 Oct 17].
   PubMed Web of Science ®Google Scholar
• Zheng W, Degterev A, Hsu E, et al. Structure-activity relationship study of a novel necroptosis inhibitor, necrostatin-7. Bioorg Med Chem Lett. 2008;18(18):4932–4935. [Epub 2008 Sep 5].
   PubMed Web of Science ®Google Scholar
• Takahashi N, Duprez L, Grootjans S, et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis. 2012;3:e437. [Epub 2012 Nov 30].
   PubMed Web of Science ®Google Scholar
• Wang D, Zhao M, Chen G, et al. The histone deacetylase inhibitor vorinostat prevents TNFα-induced necroptosis by regulating multiple signaling pathways. Apoptosis. 2013;18(11):1348–1362. [Epub 2013 May 28].
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367(22):2075–2088. [Epub 2012 Nov 30].
   PubMed Web of Science ®Google Scholar
• O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401–412. [Epub 2009 Nov 3].
   PubMed Web of Science ®Google Scholar
• Ward JE, Stadler WM. Pazopanib in renal cell carcinoma. Clin Cancer Res. 2010;16(24):5923–5927. [Epub 2010 Nov 10].
   PubMed Web of Science ®Google Scholar
• van der Graaf WTA, Gelderblom H. New systemic therapy options for advanced sarcomas. Curr Treat Options Oncol. 2012;13(3):306–317. [Epub 2012 Jun 5].
   PubMed Web of Science ®Google Scholar
• Fauster A, Rebsamen M, Huber KV, et al. A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis. Cell Death Dis. 2015;6:e1767. [Epub 2015 May 23].
   PubMed Web of Science ®Google Scholar
• Zou C, Xiong Y, Huang LY, et al. Design, synthesis, and biological evaluation of 1-Benzyl-1H-pyrazole derivatives as receptor interacting protein 1 kinase inhibitors. Chem Biol Drug Des. 2016;87(4):569–574. [Epub 2015 Nov 19].
   PubMed Web of Science ®Google Scholar
• Sun L, Wang H, Wang Z, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148(1–2):213–227. [Epub 2012 Jan 24].
   PubMed Web of Science ®Google Scholar
• Harris PA, Bandyopadhyay D, Berger SB, et al. Discovery of small molecule RIP1 kinase inhibitors for the treatment of pathologies associated with necroptosis. ACS Med Chem Lett. 2013;4(12):1238–1243. [Epub 2014 Jun 6].
   PubMed Web of Science ®Google Scholar
• Hildebrand JM, Tanzer MC, Lucet IS, et al. Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. Proc Natl Acad Sci USA. 2014;111(42):15072–15077. [Epub 2014 Oct 8].
   PubMed Web of Science ®Google Scholar
• Dodo K, Katoh M, Shimizu T, et al. Inhibition of hydrogen peroxide-induced necrotic cell death with 3-amino-2-indolylmaleimide derivatives. Bioorg Med Chem Lett. 2005;15(12):3114–3118. [Epub 2005 May 10].
   PubMed Web of Science ®Google Scholar
• Kim HJ, Koo SY, Ahn BH, et al. NecroX as a novel class of mitochondrial reactive oxygen species and ONOO(-) scavenger. Arch Pharm Res. 2010;33(11):1813–1823. [Epub 2010 Dec 1].
   PubMed Web of Science ®Google Scholar
• Orrenius S, Gogvadze V, Zhivotovsky B. Mitochondrial oxidative stress: implications for cell death. Annu Rev Pharmacol Toxicol. 2007 ;47:143–183.[Epub 2006 Oct 13].
   PubMed Web of Science ®Google Scholar
• Ott M, Gogvadze V, Orrenius S, et al. Mitochondria, oxidative stress and cell death. Apoptosis. 2007;12(5):913–922. [Epub 2007 Apr 25].
   PubMed Web of Science ®Google Scholar
• Martinet W, Schrijvers DM, De Meyer GR. Necrotic cell death in atherosclerosis. Basic Res Cardiol. 2011;106(5):749–760. [Epub 2011 May 26].
   PubMed Web of Science ®Google Scholar
• Choi JM, Park KM, Kim SH, et al. Effect of necrosis modulator necrox-7 on hepatic ischemia-reperfusion injury in beagle dogs. Transplant Proc. 2010;42(9):3414–3421. [Epub 2010 Nov 26].
   PubMed Web of Science ®Google Scholar
• Chung HK, Kim YK, Park JH, et al. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation. Liver Int. 2015;35(4):1341–1353. [Epub 2014 Dec 3].
   PubMed Web of Science ®Google Scholar
• Im KI, Kim N, Lim JY, et al. The free radical scavenger NecroX-7 attenuates acute graft-versus-host disease via reciprocal regulation of Th1/Regulatory T cells and inhibition of HMGB1 release. J Immunol. 2015;194(11):5223–5232. [Epub 2015 Apr 26].
   PubMed Web of Science ®Google Scholar
• Park J, Park E, Ahn BH, et al. NecroX-7 prevents oxidative stress-induced cardiomyopathy by inhibition of NADPH oxidase activity in rats. Toxicol Appl Pharmacol. 2012;263(1):1–6. [Epub 2012 Jun 5].
   PubMed Web of Science ®Google Scholar
• Park JH, Seo KS, Tadi S, et al. An indole derivative protects against acetaminophen-induced liver injury by directly binding to N-acetyl-p-benzoquinone imine in mice. Antioxid Redox Signal. 2013;18(14):1713–1722. [Epub 2012 Nov 6].
   PubMed Web of Science ®Google Scholar
• Thu VT, Kim HK, Long Le T, et al. NecroX-5 prevents hypoxia/reoxygenation injury by inhibiting the mitochondrial calcium uniporter. Cardiovasc Res. 2012;94(2):342–350. [Epub 2012 Mar 20].
   PubMed Web of Science ®Google Scholar
• Najjar M, Suebsuwong C, Ray SS, et al. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. Cell Rep. 2015;10(11):1850–1860.
   PubMed Web of Science ®Google Scholar
• Xuan M, Okazaki M, Iwata N, et al. Chronic treatment with a water-soluble extract from the culture medium of ganoderma lucidum mycelia prevents apoptosis and necroptosis in Hypoxia/Ischemia-induced injury of type 2 diabetic mouse brain. Evid Based Complement Alternat Med. 2015;2015:865986. [Epub 2015 May/7].
   PubMed Web of Science ®Google Scholar
• Sanodiya BS, Thakur GS, Baghel RK, et al. Ganoderma lucidum: a potent pharmacological macrofungus. Curr Pharm Biotechnol. 2009;10(8):717–742. [Epub 2009 Nov 27].
   PubMed Web of Science ®Google Scholar
• Iwata N, Okazaki M, Nakano R, et al. Diabetes-mediated exacerbation of neuronal damage and inflammation after cerebral ischemia in rat: protective effects of water-soluble extract from culture medium of Ganoderma lucidum mycelia. In: Balestrino M, editor. Advances in the preclinical study of ischemic stroke. Rijeka (Croatia): Intech; 2012.
   Google Scholar
• Lee Y, Byun HS, Seok JH, et al. Terminalia Chebula provides protection against dual modes of necroptotic and apoptotic cell death upon death receptor ligation. Sci Rep. 2016;6:25094. [Epub 2016 Apr 28].
   PubMed Web of Science ®Google Scholar
• Mishra V, Agrawal M, Onasanwo SA, et al. Anti-secretory and cyto-protective effects of chebulinic acid isolated from the fruits of Terminalia chebula on gastric ulcers. Phytomedicine. 2013;20(6):506–511. [Epub 2013 Mar 7].
   PubMed Web of Science ®Google Scholar
• Park JH, Joo HS, Yoo KY, et al. Extract from Terminalia chebula seeds protect against experimental ischemic neuronal damage via maintaining SODs and BDNF levels. Neurochem Res. 2011;36(11):2043–2050. [Epub 2011 Jun 15].
   PubMed Web of Science ®Google Scholar
• Silawat N, Gupta VB. Chebulic acid attenuates ischemia reperfusion induced biochemical alteration in diabetic rats. Pharm Biol. 2013;51(1):23–29. [Epub 2012 Sep 12].
   PubMed Web of Science ®Google Scholar
• Choi MK, Kim HG, Han JM, et al. Hepatoprotective effect of terminalia chebula against t-BHP-induced acute liver injury in C57/BL6 mice. Evid Based Complement Alternat Med. 2015;2015:517350. [Epub 2015 Feb 19].
   PubMedGoogle Scholar
• Korani MS, Farbood Y, Sarkaki A, et al. Protective effects of gallic acid against chronic cerebral hypoperfusion-induced cognitive deficit and brain oxidative damage in rats. Eur J Pharmacol. 2014;733:62–67. [Epub 2014 Apr 15].
   PubMed Web of Science ®Google Scholar
• Walia H, Kumar S, Arora S. Comparative analysis of antioxidant and phenolic content of chloroform extract/fraction of Terminalia chebula. J Basic Clin Pharm. 2011;2(2):115–124. [Epub 2011 Mar 1].
   PubMedGoogle Scholar
• Mahesh R, Bhuvana S, Begum VM. Effect of Terminalia chebula aqueous extract on oxidative stress and antioxidant status in the liver and kidney of young and aged rats. Cell Biochem Funct. 2009;27(6):358–363. [Epub 2009 Jun 24].
   PubMed Web of Science ®Google Scholar
• Byun HS, Park KA, Won M, et al. Phorbol 12-myristate 13-acetate protects against tumor necrosis factor (TNF)-induced necrotic cell death by modulating the recruitment of TNF receptor 1-associated death domain and receptor-interacting protein into the TNF receptor 1 signaling complex: implication for the regulatory role of protein kinase C. Mol Pharmacol. 2006;70(3):1099–1108. [Epub 2006 Jun 27].
   PubMed Web of Science ®Google Scholar
• Li D, Li C, Li L, et al. Natural product kongensin A is a non-canonical HSP90 inhibitor that blocks RIP3-dependent necroptosis. Cell Chem Biol. 2016;23(2):257–266. [Epub 2016 Mar 31].
   PubMed Web of Science ®Google Scholar
• Workman P, Burrows F, Neckers L, et al. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci. 2007;1113:202–216. [Epub 2007 May 22].
   PubMed Web of Science ®Google Scholar
• Trott A, West JD, Klaic L, et al. Activation of heat shock and antioxidant responses by the natural product celastrol: transcriptional signatures of a thiol-targeted molecule. Mol Biol Cell. 2008;19(3):1104–1112. [Epub 2008 Jan 18].
   PubMed Web of Science ®Google Scholar
• Abbas S, Bhoumik A, Dahl R, et al. Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin Cancer Res. 2007;13(22 Pt 1):6769–6778. [Epub 2007 Nov 17].
   PubMed Web of Science ®Google Scholar
• Pinna GF, Fiorucci M, Reimund JM, et al. Celastrol inhibits pro-inflammatory cytokine secretion in Crohn’s disease biopsies. Biochem Biophys Res Commun. 2004;322(3):778–786. [Epub 2004 Sep 1].
   PubMed Web of Science ®Google Scholar
• Shaker ME, Ashamallah SA, Houssen ME. Celastrol ameliorates murine colitis via modulating oxidative stress, inflammatory cytokines and intestinal homeostasis. Chem Biol Interact. 2014;210:26–33. [Epub 2014 Jan 5].
   PubMed Web of Science ®Google Scholar
• Jia Z, Xu C, Shen J, et al. The natural compound celastrol inhibits necroptosis and alleviates ulcerative colitis in mice. Int Immunopharmacol. 2015;29(2):552–559. [Epub 2015 Oct 12].
   PubMed Web of Science ®Google Scholar
• Chtourou Y, Fetoui H, Jemai R, et al. Naringenin reduces cholesterol-induced hepatic inflammation in rats by modulating matrix metalloproteinases-2, 9 via inhibition of nuclear factor kappaB pathway. Eur J Pharmacol. 2015;746:96–105. [Epub 2014 Dec 3].
   PubMed Web of Science ®Google Scholar
• Ahmed LA, Obaid AA, Zaki HF, et al. Naringenin adds to the protective effect of L-arginine in monocrotaline-induced pulmonary hypertension in rats: favorable modulation of oxidative stress, inflammation and nitric oxide. Eur J Pharm Sci. 2014;62:161–170. [Epub 2014 Jun 1].
   PubMed Web of Science ®Google Scholar
• Assini JM, Mulvihill EE, Sutherland BG, et al. Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr(-)/(-) mice. J Lipid Res. 2013;54(3):711–724. [Epub 2012 Dec 28].
   PubMed Web of Science ®Google Scholar
• Chtourou Y, Slima AB, Makni M, et al. Naringenin protects cardiac hypercholesterolemia-induced oxidative stress and subsequent necroptosis in rats. Pharmacol Rep. 2015;67(6):1090–1097. [Epub 2015 Oct 21].
   PubMed Web of Science ®Google Scholar
• Liu W, Fan Z, Han Y, et al. Curcumin attenuates peroxynitrite-induced neurotoxicity in spiral ganglion neurons. Neurotoxicology. 2011;32(1):150–157. [Epub 2010 Sep 28].
   PubMed Web of Science ®Google Scholar
• Tiwari V, Chopra K. Attenuation of oxidative stress, neuroinflammation, and apoptosis by curcumin prevents cognitive deficits in rats postnatally exposed to ethanol. Psychopharmacology (Berl). ;224(4):519–535.2012 [Epub 2012 Jul 14].
   PubMed Web of Science ®Google Scholar
• Luo Y, Hattori A, Munoz J, et al. Intrastriatal dopamine injection induces apoptosis through oxidation-involved activation of transcription factors AP-1 and NF-kappaB in rats. Mol Pharmacol. 1999;56(2):254–264. [Epub 1999 Jul 27].
   PubMed Web of Science ®Google Scholar
• Jaisin Y, Thampithak A, Meesarapee B, et al. Curcumin I protects the dopaminergic cell line SH-SY5Y from 6-hydroxydopamine-induced neurotoxicity through attenuation of p53-mediated apoptosis. Neurosci Lett. 2011 ;489(3):192–196.[Epub 2010 Dec 21].
   PubMed Web of Science ®Google Scholar
• Du XX, Xu HM, Jiang H, et al. Curcumin protects nigral dopaminergic neurons by iron-chelation in the 6-hydroxydopamine rat model of Parkinson’s disease. Neurosci Bull. 2012;28(3):253–258. [Epub 2012 May 25].
   PubMed Web of Science ®Google Scholar
• Gupta SC, Prasad S, Kim JH, et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep. 2011;28(12):1937–1955. [Epub 2011 Oct 8].
   PubMed Web of Science ®Google Scholar
• Dai MC, Zhonga ZH, Suna YH, et al. Curcumin protects against iron induced neurotoxicity in primary cortical neurons by attenuating necroptosis. Neurosci Lett. 2013;536:41–46. [Epub 2013 Jan 14].
   PubMed Web of Science ®Google Scholar
• Yuan J, Yuan C, Degterev A. Unsaturated heterocyclic inhibitors of necroptosis. WO 2010075290 Al. 2010.
   Google Scholar
• Yuan J, Hsu ES. Small molecule inhibitors of necroptosis. US 20120122889 A1. 2012.
   Google Scholar
• Yuan J, Hsu ES. Small molecule inhibitors of necroptosis. US 20140024657 A1. 2014.
   Google Scholar
• Yuan J, Degterev A, Hitomi J, et al. Tricyclic necrostatin compounds. US 8324262 B2. 2012.
   Google Scholar
• Yuan J, Degterev A, Cuny GD. Deuterated heterocyclic inhibitors of necroptosis. WO2014152182 A1. 2014a.
   Google Scholar
• Yuan J, Degterev A, Cuny GD. Hybrid necroptosis inhibitors. US20140323489 A1. 2014b.
   Google Scholar
• Cuny GD, Yuan J, Degterev A. Heterocyclic inhibitors of necroptosis. US8278344 B2. 2012.
   Google Scholar
• Cuny GD, Teng X, Yuan J, et al. Heterocyclic inhibitors of necroptosis. US 8658689 B2. 2014a.
   Google Scholar
• Cuny GD, Teng X, Yuan J, et al. Heterocyclic inhibitors of necroptosis.US 20140128437 A1. 2014b.
   Google Scholar
• Cuny GD, Teng X, Yuan J, et al. Heterocyclic inhibitors of necroptosis. US 20160102053 A1. 2016.
   Google Scholar
• Conrad M, Schick J, Proneth B, et al. Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death. WO 2015007730 A1. 2015.
   Google Scholar